Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade

Annual Review of Biochemistry

Volumn 86, Issue , 2017, Pages 27-68

  Chiti, Fabrizio ^a   Dobson, Christopher M ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Amyloidosis; Chaperones; Conformational diseases; Functional amyloid; Protein aggregation; Protein homeostasis; Quality control

Indexed keywords

ALPHA SYNUCLEIN; AMYLIN; AMYLOID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN C2; CALCITONIN; HUNTINGTIN; LYSOZYME; MICROTUBULE ASSOCIATED PROTEIN; PREALBUMIN; PRION PROTEIN; PROLACTIN; SERUM AMYLOID A; TAU PROTEIN; CHAPERONE; NEW DRUG;

HEREDITY; HUMAN; PATHOGENICITY; PLASTICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN MISFOLDING; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; REVIEW; ALZHEIMER DISEASE; AMYLOIDOSIS; CHEMISTRY; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GENETICS; HISTORY; METABOLISM; MOLECULARLY TARGETED THERAPY; PARKINSON DISEASE; PATHOLOGY; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES;

ALZHEIMER DISEASE; AMYLOID; AMYLOIDOSIS; DIABETES MELLITUS, TYPE 2; DRUGS, INVESTIGATIONAL; GENE EXPRESSION REGULATION; HISTORY, 21ST CENTURY; HUMANS; MOLECULAR CHAPERONES; MOLECULAR TARGETED THERAPY; PARKINSON DISEASE; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES;

EID: 85020890340     PISSN: 00664154     EISSN: 15454509     Source Type: Book Series    
DOI: 10.1146/annurev-biochem-061516-045115     Document Type: Review

References (243)

1. Chiti F, Dobson CM. (2006). Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75: 333-66
2. Guijarro JI, Sunde M, Jones JA, Campbell ID, Dobson CM. (1998). Amyloid fibril formation by an SH3 domain. PNAS 95: 4224-28
3. Chiti F, Webster P, Taddei N, Clark A, Stefani M, et al. (1999). Designing conditions for in vitro formation of amyloid protofilaments and fibrils. PNAS 96: 3590-94
4. Fändrich M, Dobson CM. (2002). The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J. 21: 5682-90
5. Adler-Abramovich L, Vaks L, Carny O, Trudler D, Magno A, et al. (2012). Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria. Nat. Chem. Biol. 8: 701-6
6. Knowles TP, Fitzpatrick AW, Meehan S, Mott HR, Vendruscolo M, et al. (2007). Role of intermolecular forces in defining material properties of protein nanofibrils. Science 318: 1900-3
7. Cherny I, Gazit E. (2008). Amyloids: not only pathological agents but also ordered nanomaterials. Angew. Chem. Int. Ed. Engl. 47: 4062-69
8. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW. (2006). Functional amyloid formation within mammalian tissue. PLOS Biol. 4: e6
9. Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, et al. (2009). Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 325: 328-32
10. Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, et al. (2012). The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 150: 339-50
11. Uversky VN. (2013). Unusual biophysics of intrinsically disordered proteins. Biochim. Biophys. Acta 1834: 932-51
12. Dobson CM. (2003). Protein folding and misfolding. Nature 426: 884-90
13. Lee J, Culyba EK, Powers ET, Kelly JW. (2011). Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat. Chem. Biol. 7: 602-9
14. Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, et al. (2012). Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149: 1048-59
15. Eakin CM, Berman AJ, Miranker AD. 2006.A native to amyloidogenic transition regulated by a backbone trigger. Nat. Struct. Mol. Biol. 13: 202-8
16. Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, et al. (2005). The biological and chemical basis for tissue-selective amyloid disease. Cell 121: 73-85
17. Bouchard M, Zurdo J, Nettleton EJ, Dobson CM, Robinson CV. (2000). Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci. 9: 1960-67
18. Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, et al. (2000). Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289: 1317-21
19. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. (2003). Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. PNAS 100: 330-35
20. Modler AJ, Gast K, Lutsch G, Damaschun G. (2003). Assembly of amyloid protofibrils via critical oligomers-a novel pathway of amyloid formation. J. Mol. Biol. 325: 135-48
21. Plakoutsi G, Bemporad F, Calamai M, Taddei N, Dobson CM, Chiti F. (2005). Evidence for a mechanism of amyloid formation involvingmolecular reorganisation within native-like precursor aggregates. J. Mol. Biol. 351: 910-22
22. Carulla N, Zhou M, Arimon M, Gairí M, Giralt E, et al. (2009). Experimental characterization of disordered and ordered aggregates populated during the process of amyloid fibril formation. PNAS 106: 7828-33
23. Bleiholder C, Dupuis NF, Wyttenbach T, Bowers MT. (2011). Ion mobility-mass spectrometry reveals a conformational conversion from random assembly to β-sheet in amyloid fibril formation. Nat Chem. 3: 172-77
24. Berger J, Hinglais N. (1968). Intercapillary deposits of IgA-Ig G. J. Urol. Nephrol. 74: 694-95
25. Glenner GG, Terry W, Harada M, Isersky C, Page D. (1971). Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 172: 1150-51
26. Jimenez-Zepeda VH. (2012). Light chain deposition disease: novel biological insights and treatment advances. Int. J. Lab. Hematol. 34: 347-55
27. Usmani SM, Zirafi O, Müller JA, Sandi-Monroy NL, Yadav JK, et al. (2014). Direct visualization of HIV-enhancing endogenous amyloid fibrils in human semen. Nat. Commun. 5: 3508
28. Monsellier E, Ramazzotti M, Taddei N, Chiti F. (2008). Aggregation propensity of the human proteome. PLOS Comput. Biol. 4: e1000199
29. Ghiso JA, Holton J, Miravalle L, Calero M, Lashley T, et al. (2001). Systemic amyloid deposits in familial British dementia. J. Biol. Chem. 276: 43909-14
30. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. (2009). Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78: 959-91
31. Koga H, Kaushik S, Cuervo AM. (2011). Protein homeostasis and aging: the importance of exquisite quality control. Ageing Res. Rev. 10: 205-15
32. Knowles TP, Vendruscolo M, Dobson CM. (2014). The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15: 384-96
33. Gajdusek DC, Gibbs CJ, Alpers M. (1966). Experimental transmission of a Kuru-like syndrome to chimpanzees. Nature 209: 794-96
34. Imran M, Mahmood S. (2011). An overview of human prion diseases. Virol. J. 8: 559
35. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, et al. (1996). A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347: 921-25
36. Prusiner SB. (2013). Biology and genetics of prions causing neurodegeneration. Annu. Rev. Genet. 47: 601-23
37. Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. (2015). Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat. Rev. Neurosci. 16: 109-20
38. Walker LC, Jucker M. (2015). Neurodegenerative diseases: expanding the prion concept. Annu. Rev. Neurosci. 38: 87-103
39. Aguzzi A, Lakkaraju AK. (2016). Cell biology of prions and prionoids: a status report. Trends Cell Biol. 26: 40-51
40. Canet D, Last AM, Tito P, Sunde M, Spencer A, et al. (2002). Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme. Nat. Struct. Biol. 9: 308-15
41. Dhulesia A, Cremades N, Kumita JR, Hsu ST, Mossuto MF, et al. (2010). Local cooperativity in an amyloidogenic state of human lysozyme observed at atomic resolution. J. Am. Chem. Soc. 132: 15580-88
42. Ahn M, Hagan CL, Bernardo-Gancedo A, De Genst E, Newby FN, et al. (2016). The significance of the location of mutations for the native-state dynamics of human lysozyme. Biophys. J. 111: 2358-67
43. Raimondi S, Guglielmi F, Giorgetti S, Di Gaetano S, Arciello A, et al. (2011). Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I. J. Mol. Biol. 407: 465-76
44. Gursky O, Mei X, Atkinson D. (2012). The crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on amyloid formation by the N-terminal fragment. Biochemistry 51: 10-18
45. Chen CD, Huff ME, Matteson J, Page L, Phillips R, et al. (2001). Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca2+ stabilization. EMBO J. 20: 6277-87
46. Page LJ, Suk JY, Huff ME, Lim HJ, Venable J, et al. (2005). Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. EMBO J. 24: 4124-32
47. Solomon JP, Page LJ, Balch WE, Kelly JW. (2012). Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention. Crit. Rev. Biochem. Mol. Biol. 47: 282-96
48. Spillantini MG, Goedert M. (2013). Tau pathology and neurodegeneration. Lancet Neurol. 12: 609-22
49. Niblock M, Gallo JM. (2012). Tau alternative splicing in familial and sporadic tauopathies. Biochem. Soc. Trans. 40: 677-80
50. Ancolio K, Dumanchin C, Barelli H, Warter JM, Brice A, et al. (1999). Unusual phenotypic alteration ofâ amyloid precursor protein (âAPP) maturation by a new Val-715 MetβAPP-770 mutation responsible for probable early-onset Alzheimer's disease. PNAS 96: 4119-24
51. De Jonghe C, Esselens C, Kumar-Singh S, Craessaerts K, Serneels S, et al. (2001). Pathogenic APP mutations near the γ-secretase cleavage site differentially affect Aβsecretion and APP C-terminal fragment stability. Hum. Mol. Genet. 10: 1665-71
52. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. (2000). BACE2, aβ-secretase homolog, cleaves at the βsite and within the amyloid-βregion of the amyloid-βprecursor protein. PNAS 97: 9712-17
53. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, et al. (2009). A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 323: 1473-77
54. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, et al. (2001). The ?Arctic? APP mutation (E693G) causes Alzheimer's disease by enhanced Aβprotofibril formation. Nat. Neurosci. 4: 887-93
55. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, et al. (2008). A new amyloid â variant favoring oligomerization in Alzheimer's-type dementia. Ann. Neurol. 63: 377-87
56. De Jonghe C, Zehr C, Yager D, Prada CM, Younkin S, et al. (1998). Flemish and Dutch mutations in amyloid βprecursor protein have different effects on amyloid βsecretion. Neurobiol. Dis. 5: 281-86
57. Armstrong J, Boada M, Rey MJ, Vidal N, Ferrer I. (2004). Familial Alzheimer disease associated with A713T mutation in APP. Neurosci. Lett. 370: 241-43
58. Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, et al. (2000). Substitutions at codon 22 of Alzheimer's Aβpeptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J. Biol. Chem. 275: 27110-16
59. Zhou L, Brouwers N, Benilova I, Vandersteen A, Mercken M, et al. (2011). Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β-site increases Aβ generation. EMBO Mol. Med. 3: 291-302
60. Ghosh D, Sahay S, Ranjan P, Salot S, Mohite GM, et al. (2014). The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding. Biochemistry 53: 6419-21
61. Flagmeier P, Meisl G, Vendruscolo M, Knowles TP, Dobson CM, et al. (2016). Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α-synuclein aggregation. PNAS 113: 10328-33
62. Caubet C, Bousset L, Clemmensen O, Sourigues Y, Bygum A, et al. (2010). A new amyloidosis caused by fibrillar aggregates of mutated corneodesmosin. FASEB J. 24: 3416-26
63. Vidal R, Frangione B, Rostagno A, Mead S, Révész T, et al. (1999). Systemic amyloid deposits in familial British dementia. Nature 399: 776-81
64. Vidal R, Révész T, Rostagno A, Kim E, Holton JL, et al. (2000). A decamer duplication in the 3 region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. PNAS 97: 4920-25
65. Benson MD, Liepnieks JJ, Yazaki M, Yamashita T, Hamidi Asl K, et al. (2001). A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 72: 272-77
66. De Gracia R, Fernández EJ, Riñón C, Selgas R, Garcia-Bustos J. (2006). Hereditary renal amyloidosis associated with a novel mutation in the apolipoprotein AII gene. QJM 99: 274
67. Srinivasan R, Jones EM, Liu K, Ghiso J, Marchant RE, Zagorski MG. (2003). pH-dependent amyloid and protofibril formation by the ABri peptide of familial British dementia. J. Mol. Biol. 333: 1003-23
68. Von Mikecz A. (2014). Pathology and function of nuclear amyloid. Protein homeostasis matters. Nucleus 5: 311-17
69. Rovelet-Lecrux A, Hannequin D, Raux G, LeMeur N, Laquerrière A, et al. (2006). APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38: 24-26
70. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003). á-Synuclein locus triplication causes Parkinson's disease. Science 302: 841
71. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al. (2004). á-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-69
72. Paravastu AK, Leapman RD, Yau WM, Tycko R. (2008). Molecular structural basis for polymorphism in Alzheimer's β-amyloid fibrils. PNAS 105: 18349-54
73. Wasmer C, Lange A, Van Melckebeke H, Siemer AB, Riek R, Meier BH. (2008). Amyloid fibrils of the HET-s(218-289) prion form a βsolenoid with a triangular hydrophobic core. Science 319: 1523-26
74. Sunde M, Blake C. (1997). The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv. Protein Chem. 50: 123-59
75. Zandomeneghi G, Krebs MR, McCammon MG, Fändrich M. (2004). FTIR reveals structural differences between native β-sheet proteins and amyloid fibrils. Protein Sci. 13: 3314-21
76. Eisenberg D, Jucker M. (2012). The amyloid state of proteins in human diseases. Cell 148: 1188-203
77. Nilsson MR. (2004). Techniques to study amyloid fibril formation in vitro. Methods 34: 151-60
78. Mathis CA, Mason NS, Lopresti BJ, Klunk WE. (2012). Development of positron emission tomography β-amyloid plaque imaging agents. Semin. Nucl. Med. 42: 423-32
79. Gazit E. (2002). The correctly folded state of proteins: Is it a metastable state? Angew. Chem. Int. Ed. Engl. 41: 257-69
80. Baldwin AJ, Knowles TP, Tartaglia GG, Fitzpatrick AW, Devlin GL, et al. (2011). Metastability of native proteins and the phenomenon of amyloid formation. J. Am. Chem. Soc. 133: 14160-63
81. Balchin D, Hayer-Hartl M, Hartl FU. (2016). In vivo aspects of protein folding and quality control. Science 353: aac4354
82. Petkova AT, Yau WM, Tycko R. (2006). Experimental constraints on quaternary structure in Alzheimer's β-amyloid fibrils. Biochemistry 45: 498-512
83. Bertini I, Gonnelli L, Luchinat C, Mao J, Nesi A. (2011). A new structural model of Aβ40 fibrils. J. Am. Chem. Soc. 133: 16013-22
84. Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R. (2013). Molecular structure of â-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154: 1257-68
85. Colvin MT, Silvers R, Ni QZ, Can TV, Sergeyev I, et al. (2016). Atomic resolution structure ofmonomorphic Aβ42 amyloid fibrils. J. Am. Chem. Soc. 138: 9663-74
86. Luca S, Yau WM, Leapman R, Tycko R. (2007). Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry 46: 13505-22
87. Weirich F, Gremer L, Mirecka EA, Schiefer S, Hoyer W, Heise H. (2016). Structural characterization of fibrils from recombinant human islet amyloid polypeptide by solid-state NMR: The central FGAILS segment is part of the β-sheet core. PLOS ONE 11: e0161243
88. Davies HA, Madine J, Middleton DA. (2015). Comparisons with amyloid-β reveal an aspartate residue that stabilizes fibrils of the aortic amyloid peptide medin. J. Biol. Chem. 290: 7791-803
89. Hoop CL, Lin HK, Kar K, Magyarfalvi G, Lamley JM, et al. (2016). Huntingtin exon 1 fibrils feature an interdigitated β-hairpin-based polyglutamine core. PNAS 113: 1546-51
90. Helmus JJ, Surewicz K, Apostol MI, Surewicz WK, Jaroniec CP. (2011). Intermolecular alignment in Y145Stop human prion protein amyloid fibrils probed by solid-state NMR spectroscopy. J. Am. Chem. Soc. 133: 13934-37
91. Müller H, Brener O, Andreoletti O, Piechatzek T, Willbold D, et al. (2014). Progress towards structural understanding of infectious sheep PrP-amyloid. Prion 8: 344-58
92. Yang Y, Petkova A, Huang K, Xu B, Hua QX, et al. (2010). An Achilles? heel in an amyloidogenic protein and its repair: insulin fibrillation and therapeutic design. J. Biol. Chem. 285: 10806-21
93. Bateman DA, Tycko R, Wickner RB. (2011). Experimentally derived structural constraints for amyloid fibrils of wild-type transthyretin. Biophys. J. 101: 2485-92
94. Daebel V, Chinnathambi S, Biernat J, Schwalbe M, Habenstein B, et al. (2012). β-Sheet core of tau paired helical filaments revealed by solid-state NMR. J. Am. Chem. Soc. 134: 13982-89
95. Itoh-Watanabe H, Kamihira-Ishijima M, Javkhlantugs N, Inoue R, Itoh Y, et al. (2013). Role of aromatic residues in amyloid fibril formation of human calcitonin by solid-state 13CNMRandmolecular dynamics simulation. Phys. Chem. Chem. Phys. 15: 8890-901
96. Su Y, Sarell CJ, Eddy MT, Debelouchina GT, Andreas LB, et al. (2014). Secondary structure in the core of amyloid fibrils formed from human β2m and its truncated variant N6. J. Am. Chem. Soc. 136: 6313-25
97. Heise H, Hoyer W, Becker S, Andronesi OC, Riedel D, Baldus M. (2005). Molecular-level secondary structure, polymorphism, and dynamics of full-length α-synuclein fibrils studied by solid-state NMR. PNAS 102: 15871-76
98. Vilar M, Chou HT, Lührs T, Maji SK, Riek-Loher D, et al. (2008). The fold of α-synuclein fibrils. PNAS 105: 8637-42
99. Comellas G, Lemkau LR, Nieuwkoop AJ, Kloepper KD, Ladror DT, et al. (2011). Structured regions of á-synuclein fibrils include the early-onset Parkinson's disease mutation sites. J. Mol. Biol. 411: 881-95
100. Gath J, Bousset L, Habenstein B, Melki R, Böckmann A, Meier BH. (2014). Unlike twins: an NMR comparison of two α-synuclein polymorphs featuring different toxicity. PLOS ONE 9: e90659
101. Gath J, Bousset L, Habenstein B, Melki R, Meier BH, Böckmann A. (2014). Yet another polymorph of α-synuclein: solid-state sequential assignments. Biomol. NMR Assign. 8: 395-404
102. Tuttle MD, Comellas G, Nieuwkoop AJ, Covell DJ, Berthold DA, et al. (2016). Solid-stateNMRstructure of a pathogenic fibril of full-length human α-synuclein. Nat. Struct. Mol. Biol. 23: 409-15
103. Van Melckebeke H, Wasmer C, Lange A, Ab E, Loquet A, et al. (2010). Atomic-resolution threedimensional structure of HET-s(218-289) amyloid fibrils by solid-state NMR spectroscopy. J. Am. Chem. Soc. 132: 13765-75
104. Vázquez-Fernández E, Vos MR, Afanasyev P, Cebey L, Sevillano AM, et al. (2016). The structural architecture of an infectious mammalian prion using electron cryomicroscopy. PLOS Pathog. 12: e1005835
105. Fitzpatrick AW, Debelouchina GT, Bayro MJ, Clare DK, Caporini MA, et al. (2013). Atomic structure and hierarchical assembly of a cross-βamyloid fibril. PNAS 110: 5468-73
106. Makin OS, Atkins E, Sikorski P, Johansson J, Serpell LC. (2005). Molecular basis for amyloid fibril formation and stability. PNAS 102: 315-20
107. Sikorski P, Atkins E. (2005). New model for crystalline polyglutamine assemblies and their connection with amyloid fibrils. Biomacromolecules 6: 425-32
108. Morris KL, Serpell LC. (2012). X-ray fibre diffraction studies of amyloid fibrils. MethodsMol. Biol. 849: 121-35
109. Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, et al. (2015). Structure of the toxic core of α-synuclein from invisible crystals. Nature 525: 486-90
110. Serag AA, Altenbach C, Gingery M, Hubbell WL, Yeates TO. (2002). Arrangement of subunits and ordering of β-strands in an amyloid sheet. Nat. Struct. Biol. 9: 734-39
111. Olofsson A, Ippel JH, Wijmenga SS, Lundgren E, Ohman A. (2004). Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy. J. Biol. Chem. 279: 5699-707
112. Lim KH, Dasari AK, Hung I, Gan Z, Kelly JW, et al. (2016). Solid-state NMR studies reveal native-like β-sheet structures in transthyretin amyloid. Biochemistry 55: 5272-78
113. Elam JS, Taylor AB, Strange R, Antonyuk S, Doucette PA, et al. (2003). Amyloid-like filaments and waterfilled nanotubes formed by SOD1 mutant proteins linked to familial ALS. Nat. Struct. Biol. 10: 461-67
114. Janowski R, Kozak M, Abrahamson M, Grubb A, Jaskolski M. (2005). 3D domain-swapped human cystatin C with amyloidlike intermolecular β-sheets. Proteins 61: 570-78
115. Sambashivan S, Liu Y, Sawaya MR, Gingery M, Eisenberg D. (2005). Amyloid-like fibrils of ribonuclease A with three-dimensional domain-swapped and native-like structure. Nature 437: 266-69
116. Guo Z, Eisenberg D. (2006). Runaway domain swapping in amyloid-like fibrils of T7 endonuclease I. PNAS 103: 8042-47
117. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. (2005). Self-propagating, molecularlevel polymorphism in Alzheimer's β-amyloid fibrils. Science 307: 262-65
118. Surmacz-Chwedoruk W, Nieznánska H, Wójcik S, Dzwolak W. (2012). Cross-seeding of fibrils from two types of insulin induces new amyloid strains. Biochemistry 51: 9460-69
119. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, et al. 2015.α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522: 340-44
120. Collinge J, Clarke AR. (2007). A general model of prion strains and their pathogenicity. Science 318: 930-36
121. Török M, Milton S, Kayed R, Wu P, McIntire T, et al. (2002). Structural and dynamic features of Alzheimer's Aβpeptide in amyloid fibrils studied by site-directed spin labeling. J. Biol. Chem. 277: 40810-15
122. Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, et al. (2005). 3D structure of Alzheimer's amyloid-β(1-42) fibrils. PNAS 102: 17342-47
123. Der-Sarkissian A, Jao CC, Chen J, Langen R. (2003). Structural organization ofα-synuclein fibrils studied by site-directed spin labeling. J. Biol. Chem. 278: 37530-35
124. Chen M, Margittai M, Chen J, Langen R. (2007). Investigation of α-synuclein fibril structure by sitedirected spin labeling. J. Biol. Chem. 282: 24970-79
125. Margittai M, Langen R. (2004). Template-assisted filament growth by parallel stacking of tau. PNAS 101: 10278-83
126. Bedrood S, Li Y, Isas JM, Hegde BG, Baxa U, et al. (2012). Fibril structure of human islet amyloid polypeptide. J. Biol. Chem. 287: 5235-41
127. Ladner CL, Chen M, Smith DP, Platt GW, Radford SE, Langen R. (2010). Stacked sets of parallel, in-register β-strands of β2-microglobulin in amyloid fibrils revealed by site-directed spin labeling and chemical labeling. J. Biol. Chem. 285: 17137-47
128. Tycko R, Savtchenko R, Ostapchenko V, Makarava N, Baskakov I. (2010). The α-helical C-terminal domain of full-length recombinant PrP converts to an in-register parallel β-sheet structure in PrP fibrils: evidence from solid state nuclear magnetic resonance. Biochemistry 49: 9488-97
129. Qiang W, Yau WM, Tycko R. (2011). Structural evolution of Iowa mutant β-amyloid fibrils from polymorphic to homogeneous states under repeated seeded growth. J. Am. Chem. Soc. 133: 4018-29
130. Belli M, Ramazzotti M, Chiti F. 2011 Prediction of amyloid aggregation in vivo. EMBO Rep. 12: 657-63
131. Pawar AP, Dubay KF, Zurdo J, Chiti F, Vendruscolo M, Dobson CM. (2005). Prediction of aggregationprone and aggregation-susceptible regions in proteins associated with neurodegenerative diseases. J. Mol. Biol. 350: 379-92
132. Tartaglia GG, Pawar AP, Campioni S, Dobson CM, Chiti F, Vendruscolo M. (2008). Prediction of aggregation-prone regions in structured proteins. J. Mol. Biol. 380: 425-36
133. Zambrano R, Jamroz M, Szczasiuk A, Pujols J, Kmiecik S, Ventura S. (2015). AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein structures. Nucleic Acids Res. 43: W306-13
134. Morozova OA, March ZM, Robinson AS, Colby DW. (2013). Conformational features of tau fibrils from Alzheimer's disease brain are faithfully propagated by unmodified recombinant protein. Biochemistry 52: 6960-67
135. Knowles TP, Waudby CA, Devlin GL, Cohen SI, Aguzzi A, et al. (2009). An analytical solution to the kinetics of breakable filament assembly. Science 326: 1533-37
136. Jarrett JT, Berger EP, Lansbury PTJr. (1993). The carboxy terminus of theâamyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-97
137. Ferrone F. (1999). Analysis of protein aggregation kinetics. Methods Enzymol. 309: 256-74
138. Morris AM, Watzky MA, Finke RG. (2009). Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. Biochim. Biophys. Acta 1794: 375-97
139. Arosio P, Knowles TP, Linse S. (2015). On the lag phase in amyloid fibril formation. Phys. Chem. Chem. Phys. 17: 7606-18
140. Chen S, Ferrone FA, Wetzel R. (2002). Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. PNAS 99: 11884-89
141. Ferrone FA. (2015). Assembly of Aβproceeds via monomeric nuclei. J. Mol. Biol. 427: 287-90
142. Masel J, Jansen VAA, Nowak MA. (1999). Quantifying the kinetic parameters of prion replication. Biophys. Chem. 77: 139-52
143. Uversky VN, Li J, Fink AL. (2001). Evidence for a partially folded intermediate in α-synuclein fibril formation. J. Biol. Chem. 276: 10737-44
144. Bhattacharyya AM, Thakur AK, Wetzel R. (2005). Polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction. PNAS 102: 15400-5
145. Pease LF 3rd, Sorci M, Guha S, Tsai DH, Zachariah MR, et al. (2010). Probing the nucleus model for oligomer formation during insulin amyloid fibrillogenesis. Biophys. J. 99: 3979-85
146. Cerdà-Costa N, De la Arada I, Avilés FX, Arrondo JL, Villegas S. (2009). Influence of aggregation propensity and stability on amyloid fibril formation as studied by Fourier transform infrared spectroscopy and two-dimensional COS analysis. Biochemistry 48: 10582-90
147. Almstedt K, Nyström S, Nilsson KP, Hammarström P. (2009). Amyloid fibrils of human prion protein are spun and woven from morphologically disordered aggregates. Prion 3: 224-35
148. Thakur AK, Jayaraman M, Mishra R, Thakur M, Chellgren VM, et al. (2009). Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat. Struct. Mol. Biol. 16: 380-89
149. Wei L, Jiang P, Xu W, Li H, Zhang H, et al. (2011). The molecular basis of distinct aggregation pathways of islet amyloid polypeptide. J. Biol. Chem. 286: 6291-300
150. Zou Y, Hao W, Li H, Gao Y, Sun Y, Ma G. (2014). New insight into amyloid fibril formation of hen egg white lysozyme using a two-step temperature-dependent FTIR approach. J. Phys. Chem. B 118: 9834-43
151. Chiti F, Dobson CM. (2009). Amyloid formation by globular proteins under native conditions. Nat. Chem. Biol. 5: 15-22
152. Banci L, Bertini I, D'Amelio N, Gaggelli E, Libralesso E, et al. (2005). Fully metallated S134N Cu, Znsuperoxide dismutase displays abnormal mobility and intermolecular contacts in solution. J. Biol. Chem. 280: 35815-21
153. Bemporad F, Chiti F. (2009). Native-like aggregation of the acylphosphatase from Sulfolobus solfataricus and its biological implications. FEBS Lett. 583: 2630-38
154. Soldi G, Bemporad F, Torrassa S, Relini A, Ramazzotti M, et al. (2005). Amyloid formation of a protein in the absence of initial unfolding and destabilization of the native state. Biophys. J. 89: 4234-44
155. Neudecker P, Robustelli P, Cavalli A, Walsh P, Lundström P, et al. (2012). Structure of an intermediate state in protein folding and aggregation. Science 336: 362-66
156. Garcia-Pardo J, Graña-Montes R, Fernandez-Mendez M, Ruyra A, Roher N, et al. (2014). Amyloid formation by human carboxypeptidase D transthyretin-like domain under physiological conditions. J. Biol. Chem. 289: 33783-96
157. Masino L, Nicastro G, Calder L, Vendruscolo M, Pastore A. (2011). Functional interactions as a survival strategy against abnormal aggregation. FASEB J. 25: 45-54
158. Ferrolino MC, Zhuravleva A, Budyak IL, Krishnan B, Gierasch LM. (2013). Delicate balance between functionally required flexibility and aggregation risk in a β-rich protein. Biochemistry 52: 8843-54
159. Kumar S, Udgaonkar JB. (2009). Structurally distinct amyloid protofibrils form on separate pathways of aggregation of a small protein. Biochemistry 48: 6441-49
160. Dinner AR, Šali A, Smith LJ, Dobson CM, Karplus M. (2000). Understanding protein folding via the free-energy surfaces from theory and experiment. Trends Biochem. Sci. 7: 331-39
161. Padrick SB, Miranker AD. (2002). Islet amyloid: Phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis. Biochemistry 41: 4694-703
162. Ramachandran G, Udgaonkar JB. (2012). Evidence for the existence of a secondary pathway for fibril growth during the aggregation of tau. J. Mol. Biol. 421: 296-314
163. Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, et al. (2013). Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. PNAS 110: 9758-63
164. Meisl G, Yang X, Hellstrand E, Frohm B, Kirkegaard JB, et al. (2014). Differences in nucleation behavior underlie the contrasting aggregation kinetics of the Aβ40 and Aβ42 peptides. PNAS 111: 9384-89
165. Buell AK, Galvagnion C, Gaspar R, Sparr E, Vendruscolo M, et al. (2014). Solution conditions determine the relative importance of nucleation and growth processes inα-synuclein aggregation. PNAS 111: 7671-76
166. Kakkar V, Månsson C, de Mattos EP, Bergink S, van der Zwaag M, et al. (2016). The S/T-rich motif in the DNAJB6 chaperone delays polyglutamine aggregation and the onset of disease in a mouse model. Mol. Cell 62: 272-83
167. Xu LQ, Wu S, Buell AK, Cohen SI, Chen LJ, et al. (2013). Influence of specific HSP70 domains on fibril formation of the yeast prion protein Ure2. Philos. Trans. R. Soc. B. 368: 20110410
168. Galvagnion C, Buell AK, Meisl G, Michaels TC, Vendruscolo M, et al. (2015). Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat. Chem. Biol. 11: 229-34
169. Arosio P, Michaels TC, Linse S, Månsson C, Emanuelsson C, et al. (2016). Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat. Commun. 7: 10948
170. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-89
171. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. (2006). A specific amyloid-βprotein assembly in the brain impairs memory. Nature 440: 352-57
172. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998). Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. PNAS 95: 6448-53
173. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, et al. (2007). Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2: 18
174. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, et al. (2009). Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J. Biol. Chem. 284: 4230-37
175. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, et al. (2005). Globular amyloidâ-peptide1-42 oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 95: 834-47
176. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, et al. (2003). Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. PNAS 100: 6370-75
177. Chimon S, Shaibat MA, Jones CR, Calero DC, Aizezi B, Ishii Y. (2007). Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate ofAlzheimer'sβ-amyloid. Nat. Struct. Mol. Biol. 14: 1157-64
178. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, et al. (2010). Structural conversion of neurotoxic amyloidbeta1-42 oligomers to fibrils. Nat. Struct. Mol. Biol. 17: 561-67
179. Podlisny MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, et al. (1995). Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem. 270: 9564-70
180. Harper JD, Wong SS, Lieber CM, Lansbury PT. (1997). Observation ofmetastable Aβamyloid protofibrils by atomic force microscopy. Chem. Biol. 4: 119-25
181. Stroud JC, Liu C, Teng PK, Eisenberg D. (2012). Toxic fibrillar oligomers of amyloid-β have cross-β structure. PNAS 109: 7717-22
182. Parthasarathy S, Inoue M, Xiao Y, Matsumura Y, Nabeshima Y, et al. (2015). Structural insight into an Alzheimer's brain-derived spherical assembly of amyloid β by solid-state NMR. J. Am. Chem. Soc. 137: 6480-83
183. O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, et al. (2010). Amyloid β-protein dimers rapidly form stable synaptotoxic protofibrils. J. Neurosci. 30: 14411-19
184. Matsumura S, Shinoda K, Yamada M, Yokojima S, Inoue M, et al. (2011). Two distinct amyloid β-protein (Aβ) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology, and toxicity analyses. J. Biol. Chem. 286: 11555-62
185. Fu Z, Aucoin D, Davis J, Van Nostrand WE, Smith SO. (2015). Mechanism of nucleated conformational conversion of Aβ42. Biochemistry 54: 4197-207
186. Lasagna-Reeves CA, Glabe CG, Kayed R. (2011). Amyloid-β annular protofibrils evade fibrillar fate in Alzheimer disease brain. J. Biol. Chem. 286: 22122-30
187. Chen SW, Drakulic S, Deas E, Ouberai M, Aprile FA, et al. (2015). Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. PNAS 112: E1994-2003
188. Gallea JI, Celej MS. (2014). Structural insights into amyloid oligomers of the Parkinson disease-related protein α-synuclein. J. Biol. Chem. 289: 26733-42
189. Lorenzen N, Nielsen SB, Buell AK, Kaspersen JD, Arosio P, et al. (2014). The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation. J. Am. Chem. Soc. 136: 3859-68
190. Zraika S, Hull RL, Verchere CB, Clark A, Potter KJ, et al. (2010). Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia 53: 1046-56
191. Almeida MR, Saraiva MJ. (2012). Clearance of extracellular misfolded proteins in systemic amyloidosis: experience with transthyretin. FEBS Lett. 586: 2891-96
192. Kastritis E, Dimopoulos MA. (2016). Recent advances in the management of AL amyloidosis. Br. J. Haematol. 172: 170-86
193. Roberts HL, Brown DR. (2015). Seeking a mechanism for the toxicity of oligomeric α-synuclein. Biomolecules 5: 282-305
194. Benilova I, Karran E, De Strooper B. (2012). The toxic Aβoligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15: 349-57
195. Guerrero-Muñoz MJ, Gerson J, Castillo-Carranza DL. (2015). Tau oligomers: the toxic player at synapses in Alzheimer's disease. Front. Cell. Neurosci. 9: 464
196. Labbadia J, Morimoto RI. (2015). The biology of proteostasis in aging and disease. Annu. Rev. Biochem. 84: 435-64
197. Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, et al. (2008). Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 27: 224-33
198. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, et al. (2009). Oligomeric amyloid βassociates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. PNAS 106: 4012-17
199. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, et al. (2010). A causative link between the structure of aberrant protein oligomers and their toxicity. Nat. Chem. Biol. 6: 140-47
200. Ladiwala AR, Litt J, Kane RS, Aucoin DS, Smith SO, et al. (2012). Conformational differences between two amyloid βoligomers of similar size and dissimilar toxicity. J. Biol. Chem. 287: 24765-73
201. Krishnan R, Goodman JL, Mukhopadhyay S, Pacheco CD, Lemke EA, et al. (2012). Conserved features of intermediates in amyloid assembly determine their benign or toxic states. PNAS 109: 11172-77
202. Bolognesi B, Kumita JR, Barros TP, Esbjorner EK, Luheshi LM, et al. (2010). ANS binding reveals common features of cytotoxic amyloid species. ACS Chem. Biol. 5: 735-40
203. Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, et al. (2011). Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144: 67-78
204. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, et al. (2001). Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79: 595-605
205. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, et al. (2003). Alzheimer's disease-affected brain: Presence of oligomeric Aβligands (ADDLs) suggests a molecular basis for reversiblememory loss. PNAS 100: 10417-22
206. Ojha J, Masilamoni G, Dunlap D, Udoff RA, Cashikar AG. (2011). Sequestration of toxic oligomers by HspB1 as a cytoprotective mechanism. Mol. Cell. Biol. 31: 3146-57
207. Mannini B, Cascella R, Zampagni M, van Waarde-Verhagen M, Meehan S, et al. (2012). Molecular mechanisms used by chaperones to reduce the toxicity of aberrant protein oligomers. PNAS 109: 12479-84
208. Cascella R, Conti S, Mannini B, Li X, Buxbaum JN, et al. (2013). Transthyretin suppresses the toxicity of oligomers formed by misfolded proteins in vitro. Biochim. Biophys. Acta 1832: 2302-14
209. Mannini B, Mulvihill E, Sgromo C, Cascella R, Khodarahmi R, et al. (2014). Toxicity of protein oligomers is rationalized by a function combining size and surface hydrophobicity. ACS Chem. Biol. 9: 2309-17
210. van Rooijen BD, Claessens MM, Subramaniam V. (2010). Membrane permeabilization by oligomeric α-synuclein: in search of the mechanism. PLOS ONE 5: e14292
211. Oropesa-Nuñez R, Seghezza S, Dante S, Diaspro A, Cascella R, et al. (2016). Interaction of toxic and nontoxic HypF-N oligomers with lipid bilayers investigated at high resolution with atomic force microscopy. Oncotarget 7: 44991-5004
212. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, et al. (2004). Permeabilization of lipid bilayers is acommonconformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279: 46363-66
213. Cremades N, Chen SW, Dobson CM. (2017). Structure characteristics ofα-synuclein oligomers. Int. Rev. Cell Mol. Biol. 329: 79-143
214. Stöckl MT, Zijlstra N, Subramaniam V. (2013). α-Synuclein oligomers: an amyloid pore? Insights into mechanisms of α-synuclein oligomer-lipid interactions. Mol. Neurobiol. 47: 613-21
215. Brehme M, Voisine C, Rolland T, Wachi S, Soper JH, et al. (2014). A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Rep. 9: 1135-50
216. Nillegoda NB, Kirstein J, Szlachcic A, Berynskyy M, Stank A, et al. (2015). Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. Nature 524: 247-51
217. Beeg M, Stravalaci M, Romeo M, Carrá AD, Cagnotto A, et al. (2016). Clusterin binds to Aβ1-42 oligomers with high affinity and interfereswith peptide aggregation by inhibiting primary and secondary nucleation. J. Biol. Chem. 291: 6958-66
218. Fernandez-Funez P, Sanchez-Garcia J, de Mena L, Zhang Y, Levites Y, et al. (2016). Holdase activity of secreted Hsp70 masks amyloid-β42 neurotoxicity in Drosophila. PNAS 113: E5212-21
219. Monsellier E, Chiti F. (2007). Prevention of amyloid-like aggregation as a driving force of protein evolution. EMBO Rep. 8: 737-42
220. Tartaglia GG, Vendruscolo M. (2009). Correlation between mRNA expression levels and protein aggregation propensities in subcellular localisations. Mol. Biosyst. 5: 1873-76
221. De Baets G, Reumers J, Delgado Blanco J, Dopazo J, Schymkowitz J, Rousseau F. (2011). An evolutionary trade-off between protein turnover rate and protein aggregation favors a higher aggregation propensity in fast degrading proteins. PLOS Comput. Biol. 7: e1002090
222. Singh S, Trikha S, Bhowmick DC, Sarkar AA, Jeremic AM. (2015). Role of cholesterol and phospholipids in amylin misfolding, aggregation and etiology of islet amyloidosis. Adv. Exp. Med. Biol. 855: 95-116
223. Hinton DR, Polk RK, Linse KD, Weiss MH, Kovacs K, Garner JA. (1997). Characterization of spherical amyloid protein from a prolactin-producing pituitary adenoma. Acta Neuropathol. 93: 43-49
224. Benditt EP, Eriksen N. (1971). Chemical classes of amyloid substance. Am. J. Pathol. 65: 231-52
225. McKinnon C, Tabrizi SJ. (2014). The ubiquitin-proteasome system in neurodegeneration. Antioxid. Redox Signal. 21: 2302-21
226. Martinez-Lopez N, Athonvarangkul D, Singh R. (2015). Autophagy and aging. Adv. Exp. Med. Biol. 847: 73-87
227. Tartaglia GG, Pechmann S, Dobson CM, Vendruscolo M. (2007). Life on the edge: a link between gene expression levels and aggregation rates of human proteins. Trends Biochem. Sci. 32: 204-6
228. Ciryam P, Tartaglia GG, Morimoto RI, Dobson CM, Vendruscolo M. (2013). Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. Cell Rep. 5: 781-90
229. Freer R, Sormanni P, Vecchi G, Ciryam P, Dobson CM, Vendruscolo M. (2016). A protein homeostasis signature in healthy brains recapitulates tissue vulnerability to Alzheimer's disease. Sci. Adv. 2: e1600947
230. Ciryam P, Kundra R, Freer R, Morimoto RI, Dobson CM, Vendruscolo M. (2016). A transcriptional signature of Alzheimer's disease is associated with a metastable subproteome at risk for aggregation. PNAS 113: 4753-58
231. Briggs R, Kennelly SP, O'Neill D. (2016). Drug treatments in Alzheimer's disease. Clin. Med. 16: 247-53
232. Valera E, Masliah E. (2016). Therapeutic approaches in Parkinson's disease and related disorders. J. Neurochem. 139: 346-52
233. Nuvolone M, Merlini G. (2017). Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol. Dial. Transplant. 32: 770-80
234. Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, et al. (2016). Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol. Ther. 5: 1-25
235. Habchi J, Chia S, Limbocker R, Mannini B, Ahn M, et al. (2017). Systematic development of small molecules to inhibit specific microscopic steps of Aâ42 aggregation in Alzheimer's disease. PNAS 114: E200-8
236. Ivanova MI, Sievers SA, Sawaya MR, Wall JS, Eisenberg D. (2009). Molecular basis for insulin fibril assembly. PNAS 106: 18990-95
237. Török M, Milton S, Kayed R, Wu P, McIntire T, et al. (2002). Structural and dynamic features of Alzheimer's Aβpeptide in amyloid fibrils studied by site-directed spin labeling. J. Biol. Chem. 277: 40810-15
238. Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, et al. (2005). 3D structure of Alzheimer's amyloid-β(1-42) fibrils. PNAS 102: 17342-47
239. Kheterpal I, Chen M, Cook KD, Wetzel R. (2006). Structural differences in Aβamyloid protofibrils and fibrils mapped by hydrogen exchange-mass spectrometry with on-line proteolytic fragmentation. J. Mol. Biol. 361: 785-95
240. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. (2002). Biochemical characterization of the core structure of α-synuclein filaments. J. Biol. Chem. 277: 19213-19
241. DelMar C, Greenbaum EA, Mayne L, Englander SW, Woods VL Jr. (2005). Structure and properties of α-synuclein and other amyloids determined at the amino acid level. PNAS 102: 15477-82
242. Kajava AV, Aebi U, Steven AC. (2005). The parallel superpleated β-structure as a model for amyloid fibrils of human amylin. J. Mol. Biol. 348: 247-52
243. Alexandrescu AT. (2013). Amide proton solvent protection in amylin fibrils probed by quenched hydrogen exchange NMR. PLOS ONE 8: e56467